JP2013518057A5 - - Google Patents

Download PDF

Info

Publication number
JP2013518057A5
JP2013518057A5 JP2012550189A JP2012550189A JP2013518057A5 JP 2013518057 A5 JP2013518057 A5 JP 2013518057A5 JP 2012550189 A JP2012550189 A JP 2012550189A JP 2012550189 A JP2012550189 A JP 2012550189A JP 2013518057 A5 JP2013518057 A5 JP 2013518057A5
Authority
JP
Japan
Prior art keywords
lys
dmt
arg
phe
trp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012550189A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518057A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/022247 external-priority patent/WO2011091357A1/en
Publication of JP2013518057A publication Critical patent/JP2013518057A/ja
Publication of JP2013518057A5 publication Critical patent/JP2013518057A5/ja
Pending legal-status Critical Current

Links

JP2012550189A 2010-01-25 2011-01-24 芳香族カチオン性ペプチドおよびその使用 Pending JP2013518057A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29806210P 2010-01-25 2010-01-25
US61/298,062 2010-01-25
PCT/US2011/022247 WO2011091357A1 (en) 2010-01-25 2011-01-24 Aromatic-cationic peptides and uses of same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015163826A Division JP2016000750A (ja) 2010-01-25 2015-08-21 芳香族カチオン性ペプチドおよびその使用

Publications (2)

Publication Number Publication Date
JP2013518057A JP2013518057A (ja) 2013-05-20
JP2013518057A5 true JP2013518057A5 (enExample) 2014-03-13

Family

ID=44307257

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012550189A Pending JP2013518057A (ja) 2010-01-25 2011-01-24 芳香族カチオン性ペプチドおよびその使用
JP2015163826A Pending JP2016000750A (ja) 2010-01-25 2015-08-21 芳香族カチオン性ペプチドおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015163826A Pending JP2016000750A (ja) 2010-01-25 2015-08-21 芳香族カチオン性ペプチドおよびその使用

Country Status (8)

Country Link
US (6) US20120329730A1 (enExample)
EP (4) EP2733150A1 (enExample)
JP (2) JP2013518057A (enExample)
CN (2) CN104725472A (enExample)
AU (2) AU2011207432A1 (enExample)
CA (2) CA3008993A1 (enExample)
HK (1) HK1208686A1 (enExample)
WO (1) WO2011091357A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3150215A1 (en) * 2009-08-24 2017-04-05 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
WO2011106717A1 (en) * 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3560508A1 (en) 2010-03-15 2019-10-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
EP3290433A1 (en) * 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN102327600A (zh) * 2011-09-14 2012-01-25 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防和治疗辐射损伤的rx31肽
CN107496899A (zh) 2011-09-29 2017-12-22 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
EP2788013A4 (en) * 2011-12-09 2015-08-19 Stealth Peptides Int Inc AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
EP3170506B1 (en) * 2012-03-30 2018-05-16 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
WO2013155334A1 (en) * 2012-04-12 2013-10-17 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
PT2968443T (pt) 2013-03-15 2021-12-28 Protagonist Therapeutics Inc Análogos de hepcidina e seus usos
US20140294902A1 (en) * 2013-04-02 2014-10-02 Protagonist Therapeutics, Inc. Novel a4b7 peptide antagonists
CA2916492A1 (en) * 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
US20160175379A1 (en) * 2013-08-12 2016-06-23 Stealth Bio Therapeutics Corp Combination therapy for the treatment of ischemia-reperfusion injury
EP3077049B1 (en) * 2013-12-02 2019-06-19 Stealth BioTherapeutics Corp Compositions for use in treating vitiligo
SG10201810321PA (en) 2014-05-16 2018-12-28 Protagonist Therapeutics Inc α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS
ES2977537T3 (es) 2014-07-17 2024-08-26 Protagonist Therapeutics Inc Inhibidores peptídicos orales del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias intestinales
SG11201702553RA (en) 2014-10-01 2017-04-27 Protagonist Therapeutics Inc NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
CA2978905A1 (en) * 2015-03-06 2016-09-15 Stealth Biotherapeutics Corp Processes for preparing pharmaceutically relevant peptides
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP6533723B2 (ja) * 2015-09-11 2019-06-19 キユーピー株式会社 抗酸化剤
WO2017093897A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
WO2017117381A1 (en) * 2015-12-31 2017-07-06 Scott Duncan Therapeutic compositions including peptides and uses thereof
CN109476700A (zh) * 2016-03-11 2019-03-15 隐形生物治疗公司 结晶盐形式
AU2017249218B2 (en) 2016-04-11 2020-08-27 Arcuate Therapeutics, Inc. Chiral peptides
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
EP4092038A1 (en) 2017-09-11 2022-11-23 Protagonist Therapeutics, Inc. Opioid agonist peptides and uses thereof
EP4501952A3 (en) 2018-02-08 2025-04-16 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
JP7606966B2 (ja) * 2018-12-18 2024-12-26 ステルス バイオセラピューティクス インコーポレイテッド ミトコンドリア病を標的とするアナログ
EP3997105A4 (en) 2019-07-10 2023-09-13 Protagonist Therapeutics, Inc. PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES
IL294680A (en) 2020-01-15 2022-09-01 Janssen Biotech Inc Peptide inhibitors of the interleukin-23 receptor and their use for the treatment of inflammatory diseases
CN115279782A (zh) 2020-01-15 2022-11-01 詹森生物科技公司 白介素-23受体的肽抑制剂及其用于治疗炎性疾病的用途
IL302996B2 (en) 2020-11-20 2025-04-01 Janssen Pharmaceutica Nv Compositions of interleukin-23 receptor peptide inhibitors
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
AU2022311814A1 (en) 2021-07-14 2024-02-29 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0273696A2 (en) * 1987-01-02 1988-07-06 Merck & Co. Inc. Renin inhibitors containing histidine replacements
WO1991006563A1 (en) * 1989-11-06 1991-05-16 Farmitalia Carlo Erba S.R.L. Reduced irreversible bombesin antagonists
JPH06509075A (ja) * 1991-07-01 1994-10-13 ユニヴァーシティ　テクノロジーズ　インターナショナル　インコーポレイテッド ＧｎＲＨ及び他の生物学的に活性なリガンドの非感度低下性類縁体
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
EP2865385B1 (en) * 2003-02-04 2016-11-16 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
CA2971928C (en) * 2004-01-23 2019-01-08 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
PL2252312T3 (pl) * 2008-02-07 2014-10-31 Univ Cornell Sposoby zapobiegania lub leczenia insulinooporności
JP5677096B2 (ja) * 2008-02-26 2015-02-25 コーネル ユニヴァーシティー 急性腎障害を予防および治療するための方法

Similar Documents

Publication Publication Date Title
JP2013518057A5 (enExample)
JP2011513241A5 (enExample)
JP2012126742A5 (enExample)
EP2326718A4 (en) INHBB EPITOP PEPTIDES AND VACCINES CONTAINING THEM
HK1215934A1 (zh) 肽治疗剂及其使用方法
CL2013003331A1 (es) Tableta de liberacion inmediata a prueba de alteracion que comprende (i) una matriz, y (ii) una pluralidad de material particulado, que comprende un opiaceo y un polimero de oxido de polietileno de mas de 20.000 g/mol, donde el multiparticulado forma una fase discontinua dentro de la matriz.
WO2011156453A3 (en) Therapeutic peptides
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
JP2013523703A5 (enExample)
WO2011094357A8 (en) Respiratory virus epitopes templated into double stranded coiled -coils and use thereof in immunization
JP2007262090A5 (enExample)
JP2014051497A5 (enExample)
WO2010009277A3 (en) Immunogenic amphipathic peptide compositions
JP2015510393A5 (enExample)
PL2010209T3 (pl) Immunogeniczne peptydy WT-1 i sposoby ich użycia
WO2009117041A3 (en) Use of pyrene to carry peptides across the blood brain barrier
JP2014532722A5 (enExample)
JP2012521201A5 (enExample)
JP2013543843A5 (enExample)
JP2013510169A5 (enExample)
JP2012529293A5 (enExample)
WO2008069917A3 (en) Novel cyclic peptides
JP2014050390A5 (enExample)
JP2010265269A5 (enExample)
CL2012003012A1 (es) Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion.